Claire de Oliveira, PhD
Expert Advisor, Cancer Economics | Canadian Partnership Against Cancer
Toronto, ON, CANADA
Dr. Claire de Oliveira's main areas include the quantification of the economic burden and the assessment of value for money.
Media
Publications:
Documents:
Videos:
Audio/Podcasts:
Biography
Dr. Claire de Oliveira joined the Canadian Partnership Against Cancer as Expert Advisor, Cancer Economics in 2016. In this role, she develops health economics expertise within the Partnership and supports efforts to deepen the capacity to quantify the burden of cancer and assess the economic impact of a coordinated, pan-Canadian approach to cancer control. She also works across cancer control initiatives to quantify efficiencies and support efforts to improve the sustainability of the cancer control system.
In addition to her work at the Partnership, Dr. de Oliveira is a Reader in Health Economics at the Centre for Health Economics and the Hull York Medical School at the University of York, UK, Health Economist at the Centre for Addiction and Mental Health, Associate Professor at the Institute of Health Policy, Management and Evaluation at the University of Toronto, and Adjunct Scientist at ICES. Her main areas of research in the cancer domain include the development of costing methodology, the measurement of the economic burden, and the assessment of value for money in cancer care.
Dr. de Oliveira holds membership with the Canadian Centre for Applied Research in Cancer Control and is one of the program leads for Health Technology Assessment. In addition, she is a collaborator at the Toronto Health Economics Technology Assessment Collaborative. Dr. de Oliveira holds a Masters of Arts degree and a Doctorate degree in economics from McMaster University. She also holds a licentiate degree in economics from the University of Oporto in Portugal.
Areas of Expertise (6)
Cancer
Health Economics
Health Services Research
Health Policy
Mental Health
Child Health
Education (2)
McMaster University: PhD, Economics 2008
McMaster University: MA, Economics 2004
Affiliations (4)
- Canadian Centre for Applied Research in Cancer Control: Member
- Canadian Centre for Applied Research in Cancer Control: Program Lead, Health Technology Assessment
- Insititute for Health Policy, Management and Evaluation, University of Toronto: Assistant Professor
- Institute for Clinical Evaluative Sciences: Adjunct Scientist
Links (6)
Articles (9)
Phase-specific and lifetime costs of cancer care in Ontario, Canada
BMC Cancer
2016 Cancer is a major public health issue and represents a significant economic burden to health care systems worldwide. The objective of this analysis was to estimate phase-specific, 5-year and lifetime net costs for the 21 most prevalent cancer sites, and remaining tumour sites combined, in Ontario, Canada.
Trends in use and cost of initial cancer treatment in Ontario: a population-based descriptive study
CMAJ Open
2013 Cancer incidence and treatment-related costs are rising in Canada. We estimated health care use and costs in the first year after diagnosis for patients with 7 common types of cancer in Ontario to examine temporal trends in patterns of care and costs...
Understanding the costs of cancer care before and after diagnosis for the 21 most common cancers in Ontario: a population-based descriptive study
CMAJ Open
2013 The first year after cancer diagnosis is a period of intensive treatment and high cost. We sought to estimate costs for the 21 most common cancers in Ontario in the 3-month period before and the first year after diagnosis...
The Out-of-Pocket Cost Burden of Cancer Care-A Systematic Literature Review
PubMed
Nicolas Iragorri, Claire de Oliveira, Natalie Fitzgerald, Beverley Essue
2021-03-15
Abstract Background: Out-of-pocket costs pose a substantial economic burden to cancer patients and their families. The purpose of this study was to evaluate the literature on out-of-pocket costs of cancer care.
The Indirect Cost Burden of Cancer Care in Canada: A Systematic Literature Review
PubMed
Nicolas Iragorri, Claire de Oliveira, Natalie Fitzgerald, Beverley Essue
2021-05-19
Abstract Background and objectives: Cancer poses a substantial health and economic burden on patients and caregivers in Canada. Previous reviews have estimated the indirect cost burden as work-related productivity losses associated with cancer. However, these estimates require updating and complementing with more comprehensive data that include relevant dimensions beyond labor market costs, such as patient time, lost leisure time and home productivity losses.
The psychosocial cost burden of cancer: A systematic literature review
PubMed
Beverley M Essue, Nicolas Iragorri, Natalie Fitzgerald, Claire de Oliveira
2020-11-29
Abstract Background and objective: Psychosocial costs, or quality of life costs, account for psychological distress, pain, suffering and other negative experiences associated with cancer. They contribute to the overall economic burden of cancer that patients experience. But this category of costs remains poorly understood. This hinders opportunities to make the best cancer control policy decisions. This study explored the psychosocial cost burden associated with cancer, how studies measure psychosocial costs and the impact of this burden.
Temporal trends in place of death for end-of-life patients: Evidence from Toronto, Canada
PubMed
Zhuolu Sun, Denise N Guerriere, Claire de Oliveira, Peter C Coyte
2020-09-28
Abstract Understanding the temporal trends in the place of death among patients in receipt of home-based palliative care can help direct health policies and planning of health resources. This paper aims to assess the temporal trends in place of death and its determinants over the past decade for patients receiving home-based palliative care. This paper also examines the impact of early referral to home-based palliative care services on patient's place of death. Survey data collected in a home-based end-of-life care program in Toronto, Canada from 2005 to 2015 were analysed using a multivariate logistic model.
Comparing Childhood Cancer Care Costs in Two Canadian Provinces
PubMed
Mary L McBride, Claire de Oliveira, Ross Duncan, Karen E Bremner, Ning Liu, Mark L Greenberg, Paul C Nathan, Paul C Rogers, Stuart J Peacock, Murray D Krahn
2020-02-15
Background: Cancer in children presents unique issues for diagnosis, treatment and survivorship care. Phase-specific comparative cost estimates are important for informing healthcare planning. Objective: The aim of this paper is to compare direct medical costs of childhood cancer by phase of care in British Columbia (BC) and Ontario (ON).
Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration
PubMed
Kelvin Chan, Seungree Nam, Bill Evans, Claire de Oliveira, Alexandra Chambers, Scott Gavura, Jeffrey Hoch, Rebecca E Mercer, Wei Fang Dai, Jaclyn Beca, Mina Tadrous, Wanrudee Isaranuwatchai
2020-01-07
Background: Oncology therapy is becoming increasingly more expensive and challenging the affordability and sustainability of drug programmes around the world. When new drugs are evaluated, health technology assessment organisations rely on clinical trials to inform funding decisions. However, clinical trials are not able to assess overall survival and generalises evidence in a real-world setting. As a result, policy makers have little information on whether drug funding decisions based on clinical trials ultimately yield the outcomes and value for money that might be expected.
Social